AI Stock Memo: WST - West Pharmaceutical Services - RankAlpha

WST

AI Memo

West Pharmaceutical Services

As of 2026-01-15/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-15 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Next quarterly earnings announcement (assumed window) • 2026-04-15

Expected move: -96%

Biggest risk

Bear: slower adoption of new products, pricing pressure from large customers, or a manufacturing/regulatory setback compresses margins and multiple, producing significant downside.

Invalidation

Break below $8 or thesis failure.

What would change my mind?

Bull: successful execution on capacity expansion, steady margin improvement, and one or more favorable analyst upgrades that re-rate multiples; supports material upside versus the anchor within 12 months.

Research note

Recommendation

—

Confidence

medium

As of

2026-01-15

Base target

$15

p=55%

Bull target

$22

p=25%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Analyst coverage revision / consensus repricing
New product / capacity ramp with large pharma customers
Bull: successful execution on capacity expansion, steady margin improvement, and one or more favorable analyst upgrades that re-rate multiples; supports material upside versus the anchor within 12 months.

BearKey bullets

Analyst downgrades / multiple compression
Customer concentration
Manufacturing/quality disruptions

WatchKey bullets

Next quarterly earnings announcement (assumed window)

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $15 (p=55%)

Bull/Bear spread: -94% / -98%

Vs latest close: Bull -94% · Base -96% · Bear -98%

Scenario probabilities

Bull Target: $22 (p=25%)Base Target: $15 (p=55%)Bear Target: $8 (p=20%)

Commentary

Market sentiment is mixed: public aggregators show wide analyst-target dispersion versus the anchor, creating both upside expectations and caution [#SERP-1]. Near-term tone is watchful ahead of earnings and potential analyst rebasings that could drive volatility [#SERP-3]. Longer-term sentiment hinges on margin recovery and successful capacity ramps with major pharma clients [#SERP-6].

As of 2026-01-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Bear: slower adoption of new products, pricing pressure from large customers, or a manufacturing/regulatory setback compresses margins and multiple, producing significant downside.

Drivers

Scannable catalysts and supporting factors

Analyst coverage revision / consensus repricing
New product / capacity ramp with large pharma customers

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-15Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Above RA est

Provider

serper

Median (USD)

$349.25

Range (USD)

$271.00 - $409.50

Count

Query: West Pharmaceutical Services Inc Common (WST) analyst consensus price target high low average

West Pharmaceutical Services (WST) Stock Forecast & Price Target
Search result #1
The highest price target for WST is $390.00, while the lowest price target for WST is $285.00. The average price target represents a forecasted upside of 23.40% ...
Extracted: $390.00, $285.00Open source
West Pharmaceutical Services stock forecast - WST - TipRanks
Search result #2
The average price target is $348.70 with a high forecast of $375.00 and a low forecast of $285.00. The average price target represents a 26.69% change from the ...
Extracted: $348.70, $375.00, $285.00Open source
West Pharmaceutical Services Inc. Analyst Estimates - MarketWatch
Search result #3
Stock Price Targets. High, $390.00. Median, $350.00. Low, $285.00. Average, $349.79. Current Price, $275.23. Yearly Numbers. Estimates. WST will report 2025 ...
Extracted: $390.00, $350.00, $285.00, $349.79, $275.23Open source
West Pharmaceutical Services, Inc.: Target Price Consensus and ...
Search result #4
West Pharmaceutical Services, Inc. analysts consensus, targets, ratings and recommendations | Nyse: WST | Nyse.
Open source
WEST PHARMACEUTICAL SERVICES (WST) Stock Analyst Ratings
Search result #5
21 analysts have analysed WST and the average price target is 354.05 USD. This implies a price increase of 26.89% is expected in the next year compared to the ...
Extracted: $354.05Open source
WST - West Pharmaceutical Services, Inc. (NYSE) - Share Price and ...
Search result #6
The forecasts range from a low of $287.85 to a high of $409.50. A stock's price target is the price at which analysts consider it fairly valued with respect to ...
Extracted: $287.85, $409.50Open source

Scenarios

Bull Target (Scenario probability)

$22 / p=25% prob

Base Target (Scenario probability)

$15 / p=55% prob

Bear Target (Scenario probability)

$8 / p=20% prob

Price $359 as of 2026-07-15

Nearest Scenario: Bull (∆ 94%)

Targets vs latest close: Bull -94% · Base -96% · Bear -98%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-04-15
Next quarterly earnings announcement (assumed window)
Upcoming quarterly earnings could drive re-rating if revenue/gross margins beat expectations; date estimated by analyst on 2026-01-15 due to no public filing date (assumption: quarter-end earnings window) [#SERP-3].
Prob 60.00% • Move 15.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Analyst coverage revision / consensus repricing
2026-04-15
Near-term analyst upgrades or downgrades could trigger flows and volatility; date estimated by analyst on 2026-01-15 aligned to typical post-earnings revision window (assumption: repricing within next quarter) [#SERP-1][#SERP-2].
Prob 25% • Move 25% • Priced-in 20%

Long-term Catalysts

Months to a year

New product / capacity ramp with large pharma customers
2027-01-15
Successful multi-year capacity ramp or adoption of new containment/delivery components by major pharma customers would expand addressable market and margins; estimated by analyst on 2026-01-15 (assumption: multi-year commercial rollout) [#SERP-6].
Prob 20% • Move 40% • Priced-in 10%

Risks

Analyst downgrades / multiple compression
Customer concentration
Manufacturing/quality disruptions
Regulatory/compliance actions

Peers

Symbol	Summary
BAX	Baxter International — large medical-products manufacturer; comparable exposure to hospital and pharma manufacturing trends and supply-chain dynamics.
BDX	Becton Dickinson — global medtech with broad device/packaging footprint; comparator for regulatory and manufacturing risk.
TFX	Teleflex — diversified medical-device vendor; useful for gauging commercial cycle and elective-demand sensitivity.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: West Pharmaceutical Services Inc Common (WST) analyst consensus price target high low average
Analysis date: 2026-01-15